https://www.pharmaradar360.com/article/staunch-biotech-competition-spurs-new-secretive-tactics-shifts-investor-approach-bef2c24268292855PharmaRadar360en2026-09-11T10:37:52.000ZStaunch biotech competition spurs new secretive tactics, shifts investor approachhttps://www.pharmaradar360.com/article/poland-s-case-against-eu-wastewater-rules-boosted-by-advocate-general-opinion-0cb3bd178f9e4c11PharmaRadar360en2026-09-11T10:18:25.000ZPoland's case against EU wastewater rules boosted by Advocate General opinionhttps://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096PharmaRadar360en2026-09-11T09:54:19.000ZEstates Safety Fund: initial schemes and associated funding allocations, 2026 to 2030https://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-7c5df69ea3cb3fa3PharmaRadar360en2026-09-11T09:53:27.000ZSet Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in Septemberhttps://www.pharmaradar360.com/article/from-tartan-army-to-biotech-deepening-scotland-s-ties-with-boston-through-new-li-882a8830a7c1ede8PharmaRadar360en2026-09-11T09:40:13.000ZFrom Tartan Army to biotech – deepening Scotland’s ties with Boston through new life sciences partnershiphttps://www.pharmaradar360.com/article/set-yourself-up-for-a-strong-2027-2-pharmaceutical-stocks-to-buy-in-september-8cc69ed199f1afbfPharmaRadar360en2026-09-11T09:35:00.000ZSet Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in Septemberhttps://www.pharmaradar360.com/article/head-of-german-venture-fund-sees-big-potential-in-danish-biotech-but-investors-a-cbacdcd980c6a8e4PharmaRadar360en2026-09-11T09:35:00.000ZHead of German venture fund sees big potential in Danish biotech – but investors are lackinghttps://www.pharmaradar360.com/article/are-you-working-with-the-non-clinical-package-for-clinical-trial-applications-se-381cb66138accd14PharmaRadar360en2026-09-11T09:34:00.000ZAre you working with the non-clinical package for clinical trial applications? See Q&A-update!https://www.pharmaradar360.com/article/rewriting-the-rules-of-genetic-medicine-with-trna-therapeutics-beyond-biotech-aee67803a2f832f6PharmaRadar360en2026-09-11T09:33:28.000ZRewriting the rules of genetic medicine with tRNA therapeutics｜Beyond Biotechhttps://www.pharmaradar360.com/article/key-approvals-positive-study-results-and-a-partnership-deal-to-fast-track-new-me-4a3eb1cbd863abcdPharmaRadar360en2026-09-11T09:25:17.000ZKey approvals, positive study results and a partnership deal to fast track new medicationshttps://www.pharmaradar360.com/article/what-regulators-ask-when-ai-touches-a-drug-application-601c189441f030a0PharmaRadar360en2026-09-11T09:25:06.000ZWhat regulators ask when AI touches a drug applicationhttps://www.pharmaradar360.com/article/trial-misses-prompt-shake-up-call-from-major-novartis-stockholder-9b04ea1f348cb183PharmaRadar360en2026-09-11T09:25:05.000ZTrial misses prompt shake-up call from major Novartis stockholderhttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-announces-acceptance-of-new-drug-application-for-12-deaaab0cc42dfe4bPharmaRadar360en2026-09-11T09:20:41.000ZShanghai Henlius Biotech, Inc. Announces Acceptance Of New Drug Application For 120 Mg (1.7 Ml) Per Vial Strength Of Biosimilar Of Denosumab HLX14https://www.pharmaradar360.com/article/meet-the-under-35s-shaping-the-future-of-biotech-0e01cfbafd7d371bPharmaRadar360en2026-09-11T09:00:00.000ZMeet the under-35s shaping the future of biotechhttps://www.pharmaradar360.com/article/aprecia-pharmaceuticals-am-is-an-important-expansion-of-the-pharmaceutical-manuf-fa4992349a80da17PharmaRadar360en2026-09-11T08:51:27.000ZAprecia Pharmaceuticals: 'AM is an important expansion of the pharmaceutical manufacturing toolbox'https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-11T08:46:02.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-11T08:26:58.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6fPharmaRadar360en2026-09-11T08:26:58.000ZFDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?https://www.pharmaradar360.com/article/reporter-s-notebook-k-biopharma-licensing-deals-are-getting-better-not-just-bigg-744ac6deb31a7e39PharmaRadar360en2026-09-11T08:24:18.000Z[Reporter’s Notebook] K-biopharma licensing deals are getting better, not just biggerhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-13-september-2026-1016782b910b7d0cPharmaRadar360en2026-09-11T08:22:23.000ZWeekly all-cause mortality surveillance: week ending 13 September 2026https://www.pharmaradar360.com/article/astadaily-earns-purity-award-from-clean-label-project-d798f43275060d64PharmaRadar360en2026-09-11T08:20:36.000ZAstadaily earns Purity Award from Clean Label Projecthttps://www.pharmaradar360.com/article/jpmorgan-initiates-dianthus-stock-at-overweight-135-target-76d704bda903e96fPharmaRadar360en2026-09-11T08:12:00.000ZJPMorgan initiates Dianthus stock at Overweight, $135 targethttps://www.pharmaradar360.com/article/biotech-students-must-step-out-of-comfort-zones-embrace-multiple-roles-suchitra-bd66bfb839665905PharmaRadar360en2026-09-11T07:57:14.000ZBiotech students must step out of comfort zones, embrace multiple roles: Suchitra Ellahttps://www.pharmaradar360.com/article/fda-clears-prelude-s-prt13722-phase-1-trial-in-hr-positive-breast-cancer-33a29eff5efb8a93PharmaRadar360en2026-09-11T07:33:49.000ZFDA Clears Prelude’s PRT13722 Phase 1 Trial in HR-Positive Breast Cancerhttps://www.pharmaradar360.com/article/limitless-biotech-coupon-code-pct15-save-15-on-research-peptides-b07e64035e883a26PharmaRadar360en2026-09-11T07:22:22.000ZLimitless Biotech Coupon Code PCT15: Save 15% on Research Peptideshttps://www.pharmaradar360.com/article/kenanga-launches-world-first-hang-seng-biotech-index-structured-warrants-258d523c61bb1937PharmaRadar360en2026-09-11T07:16:49.000ZKenanga launches world first Hang Seng Biotech Index structured warrantshttps://www.pharmaradar360.com/article/marquis-who-s-who-honors-kenneth-hesterman-for-expertise-in-pharmaceutical-accou-4cd9960720360d81PharmaRadar360en2026-09-11T07:02:04.000ZMarquis Who's Who Honors Kenneth Hesterman for Expertise in Pharmaceutical Account Managementhttps://www.pharmaradar360.com/article/pharmaceutical-excipients-market-to-reach-usd-24-88-billion-by-2035-at-8-1-cagr-e55ec71af1e14859PharmaRadar360en2026-09-11T06:57:00.000ZPharmaceutical Excipients Market to reach USD 24.88 Billion by 2035 at 8.1% CAGRhttps://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107eePharmaRadar360en2026-09-11T06:45:32.000ZNovartis Says Closely Watched Cholesterol Study Failed to Meet Goalhttps://www.pharmaradar360.com/article/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults-b7ea1dfa91dfde4ePharmaRadar360en2026-09-11T06:38:44.000ZPhase 3 study shows aQIVc superior to comparators in older adultshttps://www.pharmaradar360.com/article/reg-rtw-biotech-opp-additional-investment-in-encoded-therapeutics-06ce266c777880acPharmaRadar360en2026-09-11T06:00:00.000ZREG - RTW Biotech Opp. - Additional investment in Encoded Therapeuticshttps://www.pharmaradar360.com/article/orzeyful-approval-might-change-the-case-for-investing-in-takeda-stock-8b50302be3cb1bfePharmaRadar360en2026-09-11T05:58:28.000ZORZEYFUL Approval Might Change The Case For Investing In Takeda Stockhttps://www.pharmaradar360.com/article/what-strong-biotech-ip-strategies-get-right-and-where-weak-ones-break-down-a2b121fe65165341PharmaRadar360en2026-09-11T05:43:37.000ZWhat Strong Biotech IP Strategies Get Right And Where Weak Ones Break Downhttps://www.pharmaradar360.com/article/comment-climate-change-threatens-pharmaceutical-companies-6987587302b518a2PharmaRadar360en2026-09-11T05:13:58.000ZComment: Climate change threatens pharmaceutical companieshttps://www.pharmaradar360.com/article/former-head-of-takeda-pharmaceutical-dies-at-80-6fc269c48465eb75PharmaRadar360en2026-09-11T05:03:00.000ZFormer head of Takeda Pharmaceutical dies at 80https://www.pharmaradar360.com/article/active-biotech-ab-publ-sto-acti-is-breakeven-near-585e562e6ced9952PharmaRadar360en2026-09-11T04:30:06.000ZActive Biotech AB (publ) (STO:ACTI): Is Breakeven Near?https://www.pharmaradar360.com/article/fda-partially-halts-trials-of-sk-biopharmaceuticals-epilepsy-drug-candidate-e77116af26fe1e1fPharmaRadar360en2026-09-11T04:17:50.000ZFDA partially halts trials of SK Biopharmaceuticals’ epilepsy drug candidatehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-senior-vp-favorite-sells-2-77m-in-stock-9fe9896a7541d2cbPharmaRadar360en2026-09-11T04:16:00.000ZWest Pharmaceutical Services senior VP favorite sells $2.77m in stockhttps://www.pharmaradar360.com/article/jiangsu-handian-biotech-lands-tens-of-millions-of-yuan-in-strategic-round-89239b47de33a798PharmaRadar360en2026-09-11T04:01:52.000ZJiangsu Handian Biotech lands tens of millions of yuan in strategic roundhttps://www.pharmaradar360.com/article/ex-takeda-pharmaceutical-head-hasegawa-dies-at-80-07ac3ad58f8939edPharmaRadar360en2026-09-11T03:54:56.000ZEx-Takeda Pharmaceutical Head Hasegawa Dies at 80https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-draws-final-us-2-million-tranche-as-phase-3-a44324072bfb26c8PharmaRadar360en2026-09-11T03:18:00.000ZParadigm Biopharmaceuticals (ASX:PAR) Draws Final US$2 Million Tranche as Phase 3 Trial Advanceshttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-secures-additional-funding-for-phase-3-clinical-tria-ddb4fb8de8310392PharmaRadar360en2026-09-11T03:07:34.000ZParadigm Biopharmaceuticals Secures Additional Funding for Phase 3 Clinical Trialhttps://www.pharmaradar360.com/article/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-0ab09b28ac07fe98PharmaRadar360en2026-09-11T03:05:00.000ZFDA Halts SK Biopharm's OPCALIM; Novartis' $12 Billion Drug Fails Phase 3https://www.pharmaradar360.com/article/laser-therapy-offers-new-hope-for-inoperable-pancreatic-tumors-aa7039f94cc04951PharmaRadar360en2026-09-11T03:01:00.000ZLaser therapy offers new hope for inoperable pancreatic tumorshttps://www.pharmaradar360.com/article/viking-therapeutics-aims-high-at-92-target-but-clinical-risks-remain-cdae87387dc82248PharmaRadar360en2026-09-11T02:54:38.000ZViking Therapeutics Aims High at $92 Target, But Clinical Risks Remainhttps://www.pharmaradar360.com/article/more-than-28-000-bottles-of-blood-pressure-drug-recalled-fda-11bf9d424e5e5c88PharmaRadar360en2026-09-11T02:31:59.000ZMore Than 28,000 Bottles of Blood Pressure Drug Recalled: FDAhttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800PharmaRadar360en2026-09-11T02:30:30.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/agenda-for-november-2026-cancer-treatments-ctac-meeting-3a6d1f5f98e260f8PharmaRadar360en2026-09-11T02:00:00.000ZAgenda for November 2026 Cancer Treatments (CTAC) meetinghttps://www.pharmaradar360.com/article/genscript-biotech-to-place-77-1-million-shares-at-hk-30-50-per-share-586a45444917dbb9PharmaRadar360en2026-09-11T01:29:44.000ZGenscript Biotech To Place 77.1 Million Shares At HK$30.50 Per Sharehttps://www.pharmaradar360.com/article/annual-iipa-debate-2026-ku-fda-plan-major-food-safety-awareness-push-in-j-k-415bf82849db4727PharmaRadar360en2026-09-11T01:24:57.000ZAnnual IIPA Debate-2026: KU, FDA plan major food-safety awareness push in J&Khttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-nyse-teva-still-a-bargain-or-fully-priced-22afb570e071b7c5PharmaRadar360en2026-09-11T01:16:33.000ZIs Teva Pharmaceutical Industries (NYSE:TEVA) Still A Bargain Or Fully Priced?https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-f4e06e3e7cd27817PharmaRadar360en2026-09-11T01:05:11.000ZUS FDA pauses new enrollment in Biohaven's epilepsy drug trialshttps://www.pharmaradar360.com/article/megazonecloud-begins-building-hanmi-pharmaceutical-s-quality-assurance-ai-agent-34906fa2a5c01536PharmaRadar360en2026-09-11T00:06:00.000ZMegazoneCloud Begins Building Hanmi Pharmaceutical's Quality Assurance AI Agent with 'AIR Studio'https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-7584d6fa6e4ae920PharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-9ef22d0b3e10454aPharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-cdd95bf3559e4cecPharmaRadar360en2026-09-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-0c0fb15eb6c3b812PharmaRadar360en2026-09-11T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-eaeaad2b1757f369PharmaRadar360en2026-09-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-fec20d0ecf6e8a08PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-e3f885ccf75002b9PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-387b96369039a218PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-7f5456fbff2a09dbPharmaRadar360en2026-09-11T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-afe80eb92a8c9c39PharmaRadar360en2026-09-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a6fe3f8b4d203625PharmaRadar360en2026-09-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-68ff035afccb0a3ePharmaRadar360en2026-09-11T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-ea300a76aa4bfbd0PharmaRadar360en2026-09-11T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-9844da1238f74937PharmaRadar360en2026-09-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-meeting-a3006d086a794e13PharmaRadar360en2026-09-11T00:00:00.000ZNational Heart, Lung, and Blood Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-cardiovascular-mach-212eaf111483ed36PharmaRadar360en2026-09-11T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Softwarehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-577ad723f444fe54PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/emran-mohammad-rn-aprn-cnp-decision-and-order-c222547fc36d6725PharmaRadar360en2026-09-11T00:00:00.000ZEmran Mohammad, RN, APRN, CNP; Decision and Orderhttps://www.pharmaradar360.com/article/joseph-john-stubbers-iii-d-o-decision-and-order-56e3d57bd217be2ePharmaRadar360en2026-09-11T00:00:00.000ZJoseph John Stubbers III, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/cheryl-white-n-p-decision-and-order-6910fc9ec09361e7PharmaRadar360en2026-09-11T00:00:00.000ZCheryl White, N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/craig-cohen-dpm-decision-and-order-bac086480e607f05PharmaRadar360en2026-09-11T00:00:00.000ZCraig Cohen, DPM; Decision and Orderhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-appalachian-region-healthcare-support-program-eb7a15e20f6e765dPharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Appalachian Region Healthcare Support Programhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-infant-toddler-court-program-state-awards-556a097130f48a79PharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Infant-Toddler Court Program-State Awardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-cbd46bd70ec39a02PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Rural Health Network Development Program Performance Improvement and Measurement System, OMB No. 0906-0010-Revisionhttps://www.pharmaradar360.com/article/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-co-bf1f21ba8881a138PharmaRadar360en2026-09-11T00:00:00.000ZAmending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylatehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-93720515e76d644fPharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Trackinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c7cf00b962ad7623PharmaRadar360en2026-09-11T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feedhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-hospital-stabilization-pilot-program-f42ef2358c137743PharmaRadar360en2026-09-11T00:00:00.000ZNotice of Supplemental Funding, Rural Hospital Stabilization Pilot Programhttps://www.pharmaradar360.com/article/national-institute-on-aging-amended-notice-of-meeting-05a388dc6e88ab98PharmaRadar360en2026-09-11T00:00:00.000ZNational Institute on Aging; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-943f33d3924a19c8PharmaRadar360en2026-09-11T00:00:00.000ZNational Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-e4c7ec9101c7b4edPharmaRadar360en2026-09-11T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/what-services-do-people-seek-when-they-visit-a-community-pharmacy-care-clinic-d0b530ddc5e44386PharmaRadar360en2026-09-11T00:00:00.000ZWhat services do people seek when they visit a community pharmacy care clinic?https://www.pharmaradar360.com/article/managing-patients-with-heart-failure-a-contemporary-practice-tool-for-pharmacist-7c408d6b46d4237cPharmaRadar360en2026-09-11T00:00:00.000ZManaging patients with heart failure: A contemporary practice tool for pharmacistshttps://www.pharmaradar360.com/article/medication-safety-in-indigenous-communities-challenges-and-interventions-1bf49ca019f7d0e2PharmaRadar360en2026-09-11T00:00:00.000ZMedication safety in Indigenous communities: Challenges and interventionshttps://www.pharmaradar360.com/article/ten-year-analysis-of-publications-by-quebec-hospital-pharmacists-8f6c95173b5e694fPharmaRadar360en2026-09-11T00:00:00.000ZTen-year analysis of publications by Quebec hospital pharmacistshttps://www.pharmaradar360.com/article/drug-related-problems-in-older-adults-with-mild-cognitive-impairment-or-dementia-96f624acc8f4f4a9PharmaRadar360en2026-09-11T00:00:00.000ZDrug-related problems in older adults with mild cognitive impairment or dementia: A cross-sectional comparison of 2 different instrumentshttps://www.pharmaradar360.com/article/management-of-a-patient-with-a-ticagrelor-rosuvastatin-interaction-an-algorithm-9d231ffd5b5bc159PharmaRadar360en2026-09-11T00:00:00.000ZManagement of a patient with a ticagrelor–rosuvastatin interaction: An algorithm-based tool kit for pharmacistshttps://www.pharmaradar360.com/article/a-call-for-the-generalist-pharmacist-bdb545612f6c918fPharmaRadar360en2026-09-11T00:00:00.000ZA call for the generalist pharmacisthttps://www.pharmaradar360.com/article/late-onset-multiple-acyl-coa-dehydrogenase-deficiency-madd-glutaric-acidemia-typ-26ad462a8ff18b6ePharmaRadar360en2026-09-11T00:00:00.000ZLate-Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD / Glutaric Acidemia Type IIC) Presenting as Chronic Sensory Ataxic Ganglionopathy, Bilateral Sensorineural Hearing Loss, and Vocal Cord Dysfunction Associated with a Novel ETFDH Varianthttps://www.pharmaradar360.com/article/successful-management-of-generalized-drug-influenced-gingival-enlargement-a-clin-a0dff0eeba02fdcaPharmaRadar360en2026-09-11T00:00:00.000ZSuccessful Management of Generalized Drug-Influenced Gingival Enlargement: A Clinical Case Reporthttps://www.pharmaradar360.com/article/clinical-phenotypes-and-factors-associated-with-systemic-involvement-in-pediatri-bb23bbedc93d5e22PharmaRadar360en2026-09-11T00:00:00.000ZClinical Phenotypes and Factors Associated with Systemic Involvement in Pediatric IgA Vasculitis: A Single-Center Study from Southeastern Türkiyehttps://www.pharmaradar360.com/article/the-ictal-interictal-continuum-a-comprehensive-review-for-the-clinical-epileptol-1d28a0773cd7a283PharmaRadar360en2026-09-11T00:00:00.000ZThe Ictal-Interictal Continuum: A Comprehensive Review for the Clinical Epileptologisthttps://www.pharmaradar360.com/article/knowledge-attitudes-and-practices-regarding-hypertension-prevention-among-medica-95ce3ccfb7d13a35PharmaRadar360en2026-09-11T00:00:00.000ZKnowledge, Attitudes, and Practices Regarding Hypertension Prevention Among Medical Students: A Cross-Sectional Study at Agostinho Neto Universityhttps://www.pharmaradar360.com/article/acupuncture-care-for-a-patient-with-tennis-elbow-lateral-elbow-tendinopathy-a-ca-55448e3e6a6b64cePharmaRadar360en2026-09-11T00:00:00.000ZAcupuncture Care For A Patient With Tennis Elbow (Lateral Elbow Tendinopathy): A Case Reporthttps://www.pharmaradar360.com/article/i-ll-see-it-when-i-believe-it-73965d6ba86bbf24PharmaRadar360en2026-09-11T00:00:00.000ZI'll See It When I Believe Ithttps://www.pharmaradar360.com/article/the-practitioner-s-guide-to-ericksonian-choice-architecture-7ba5e46554ae733ePharmaRadar360en2026-09-11T00:00:00.000ZThe Practitioner's Guide to Ericksonian Choice Architecturehttps://www.pharmaradar360.com/article/effectiveness-of-olfactory-training-and-topical-corticosteroids-for-persistent-p-284ef17782a9bce4PharmaRadar360en2026-09-11T00:00:00.000ZEffectiveness of olfactory training and topical corticosteroids for persistent post-COVID-19 anosmia and hyposmia: A prospective randomized controlled trialhttps://www.pharmaradar360.com/article/future-directions-b7312a04957ae1cbPharmaRadar360en2026-09-11T00:00:00.000ZFuture Directionshttps://www.pharmaradar360.com/article/teaching-the-invisible-a-game-based-simulation-for-learning-health-care-economic-7ea5cdfe5504fe20PharmaRadar360en2026-09-11T00:00:00.000ZTeaching the Invisible: A Game-Based Simulation for Learning Health Care Economics in Clinical Nurse Leader Educationhttps://www.pharmaradar360.com/article/pre-diagnostic-identification-of-cholestatic-liver-diseases-using-integrated-cli-89d880bf052825c6PharmaRadar360en2026-09-11T00:00:00.000ZPre-diagnostic identification of cholestatic liver diseases using integrated clinical and environmental data frameworkhttps://www.pharmaradar360.com/article/localization-of-advanced-drug-delivery-manufacturing-in-saudi-arabia-through-tec-a5d3d641a0ae9b7dPharmaRadar360en2026-09-11T00:00:00.000ZLocalization of Advanced Drug-Delivery Manufacturing in Saudi Arabia Through Technology Transfer and Pharmaceutical Process Scale-Uphttps://www.pharmaradar360.com/article/predictive-analysis-of-social-determinants-of-health-in-posterior-cervical-spine-990d69caca0e348fPharmaRadar360en2026-09-11T00:00:00.000ZPredictive Analysis of Social Determinants of Health in Posterior Cervical Spine Surgeryhttps://www.pharmaradar360.com/article/association-between-physical-therapy-and-mortality-in-older-patients-with-heart-9c687d7a8b736236PharmaRadar360en2026-09-11T00:00:00.000ZAssociation Between Physical Therapy and Mortality in Older Patients with Heart Failure and Chronic Kidney Diseasehttps://www.pharmaradar360.com/article/hydrus-microstent-combined-with-cataract-surgery-in-pseudoexfoliation-glaucoma-v-da281f09101151eaPharmaRadar360en2026-09-11T00:00:00.000ZHydrus® Microstent Combined with Cataract Surgery in Pseudoexfoliation Glaucoma Versus Primary Open Angle Glaucomahttps://www.pharmaradar360.com/article/functional-status-and-postoperative-outcomes-after-left-pancreatectomy-for-pancr-ece63d7def3a3618PharmaRadar360en2026-09-11T00:00:00.000ZFunctional Status and Postoperative Outcomes After Left Pancreatectomy for Pancreatic Neuroendocrine Tumors: An Exploratory Analysis from the Prospective SPANDISPAN Studyhttps://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-management-of-spontaneous-esophageal-perfora-729725021ca6e7c5PharmaRadar360en2026-09-11T00:00:00.000ZDiagnostic Approach and Therapeutic Management of Spontaneous Esophageal Perforation (Boerhaave’s Syndrome): A Systematic Review and Individual Patient-Level Pooled Analysishttps://www.pharmaradar360.com/article/the-implementation-and-clinical-validation-of-a-whole-genome-sequencing-non-inva-5efd029892d9731cPharmaRadar360en2026-09-11T00:00:00.000ZThe Implementation and Clinical Validation of a Whole-Genome Sequencing Non-Invasive Prenatal Test in a High-Complexity Clinical Laboratory: A Retrospective Analysis of 11,235 Pregnancieshttps://www.pharmaradar360.com/article/risk-stratification-of-acute-symptomatic-anterior-circulation-intracranial-ather-060335b18fc361eePharmaRadar360en2026-09-11T00:00:00.000ZRisk stratification of acute symptomatic anterior circulation intracranial atherosclerotic stenosis using an ABCD3-I-informed clinical-imaging score: an exploratory studyhttps://www.pharmaradar360.com/article/a-clinical-study-of-simotang-oral-liquid-combined-with-shenque-acupoint-applicat-d4b5d7677424f285PharmaRadar360en2026-09-11T00:00:00.000ZA clinical study of Simotang oral liquid combined with Shenque acupoint application for abdominal distension after cesarean sectionhttps://www.pharmaradar360.com/article/fusion-level-selection-in-posterior-hemivertebra-resection-for-congenital-scolio-4356d58d5169b806PharmaRadar360en2026-09-11T00:00:00.000ZFusion level selection in posterior hemivertebra resection for congenital scoliosis: clinical effect size driven feature selection and multi-criteria optimization decision modelhttps://www.pharmaradar360.com/article/rethinking-ai-in-clinical-decision-support-a-framework-for-reciprocal-human-ai-i-1420c6c6866df483PharmaRadar360en2026-09-11T00:00:00.000ZRethinking AI in clinical decision support: a framework for reciprocal human-AI interactionhttps://www.pharmaradar360.com/article/clinical-efficacy-of-radix-arnebiae-oil-in-patients-undergoing-incision-and-drai-58f0e461772494f1PharmaRadar360en2026-09-11T00:00:00.000ZClinical efficacy of Radix Arnebiae oil in patients undergoing incision and drainage of perianal abscess and its effects on pyroptosishttps://www.pharmaradar360.com/article/fetal-behavior-as-a-window-to-later-gross-motor-function-a-10-year-follow-up-of-c8f670e65987c96ePharmaRadar360en2026-09-11T00:00:00.000ZFetal behavior as a window to later gross motor function: a 10-year follow-up of children prenatally exposed to gestational diabetes mellitushttps://www.pharmaradar360.com/article/clinical-and-laboratory-criteria-for-a-differentiated-approach-to-the-management-d489377a752957d5PharmaRadar360en2026-09-11T00:00:00.000ZClinical and laboratory criteria for a differentiated approach to the management of children harboring opportunistic protozoa: a retrospective analysishttps://www.pharmaradar360.com/article/efficacy-of-dapagliflozin-in-the-treatment-of-patients-with-signs-of-cardio-rena-d4a6bb4196d21d84PharmaRadar360en2026-09-11T00:00:00.000ZEFFICACY OF DAPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH SIGNS OF CARDIO-RENAL-METABOLIC SYNDROMEhttps://www.pharmaradar360.com/article/clinical-rationale-for-individualizing-secondary-prevention-in-patients-with-ath-c7a775dd082043baPharmaRadar360en2026-09-11T00:00:00.000ZCLINICAL RATIONALE FOR INDIVIDUALIZING SECONDARY PREVENTION IN PATIENTS WITH ATHEROTHROMBOTIC STROKE BASED ON PLATELET AGGREGATION MONITORINGhttps://www.pharmaradar360.com/article/clinical-characteristics-and-surgical-outcomes-of-split-cord-malformations-a-ret-a259bf8535951c1fPharmaRadar360en2026-09-11T00:00:00.000ZClinical characteristics and surgical outcomes of split cord malformations: A retrospective analysishttps://www.pharmaradar360.com/article/integrating-computed-tomography-and-magnetic-resonance-imaging-education-into-a-916bc317b1b11c9cPharmaRadar360en2026-09-11T00:00:00.000ZIntegrating Computed Tomography and Magnetic Resonance Imaging education into a clinical clerkship through specialist-led, case-based learning: a mixed-methods evaluationhttps://www.pharmaradar360.com/article/preparation-and-characterization-of-chitosan-co-acrylamide-hydrogels-for-control-6272337bb2bce876PharmaRadar360en2026-09-11T00:00:00.000ZPreparation and characterization of chitosan-co-acrylamide hydrogels for controlled drug deliveryhttps://www.pharmaradar360.com/article/enhancing-guideline-directed-medical-therapy-at-discharge-through-collaborative-61c425f8c65f8565PharmaRadar360en2026-09-11T00:00:00.000ZEnhancing Guideline-Directed Medical Therapy at Discharge Through Collaborative Care: Evidence from the TIME-HF Cluster Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-relevance-of-accuracy-in-in-house-3d-printing-in-craniomaxillofacial-su-5d29ff74d526eef8PharmaRadar360en2026-09-11T00:00:00.000ZClinical relevance of accuracy in in-house 3D printing in craniomaxillofacial surgery: a comparative study of FFF, SLA, and MJ technologieshttps://www.pharmaradar360.com/article/effect-of-theory-based-health-education-intervention-in-improving-exclusive-brea-3c22484e4d298979PharmaRadar360en2026-09-11T00:00:00.000ZEffect of theory-based health education intervention in improving exclusive breastfeeding intention among working mothers: a study protocol for a cluster randomised controlled trialhttps://www.pharmaradar360.com/article/evaluation-of-the-feasibility-usability-and-preliminary-effects-of-an-mhealth-in-61c938230b152285PharmaRadar360en2026-09-11T00:00:00.000ZEvaluation of the feasibility, usability, and preliminary effects of an mHealth intervention complementary to usual care in individuals with heart failure: protocol for a pilot randomized clinical trialhttps://www.pharmaradar360.com/article/clinical-outcomes-of-cavaterm-thermal-balloon-endometrial-ablation-in-women-with-9a5696678c3b99a8PharmaRadar360en2026-09-11T00:00:00.000ZClinical outcomes of cavaterm thermal balloon endometrial ablation in women with refractory abnormal uterine bleeding: a multicenter retrospective cohort studyhttps://www.pharmaradar360.com/article/alveolar-ridge-preservation-using-advanced-platelet-rich-fibrin-versus-concentra-642458687bb7b17cPharmaRadar360en2026-09-11T00:00:00.000ZAlveolar ridge preservation using advanced platelet-rich fibrin versus concentrated growth factors: a randomized, controlled trialhttps://www.pharmaradar360.com/article/effect-of-low-dose-esketamine-on-quality-of-recovery-after-gynecologic-laparosco-9565882e22d28941PharmaRadar360en2026-09-11T00:00:00.000ZEffect of low-dose esketamine on quality of recovery after gynecologic laparoscopic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/salivary-lysozymes-anti-inflammatory-cardiac-medications-and-cardiovascular-mort-595fc7d8250f6e70PharmaRadar360en2026-09-11T00:00:00.000ZSalivary Lysozymes, Anti-inflammatory Cardiac Medications, and Cardiovascular Mortalityhttps://www.pharmaradar360.com/article/the-association-between-hormonal-contraceptives-and-lower-extremity-injuries-in-7f2bf0b2935043e0PharmaRadar360en2026-09-11T00:00:00.000ZThe Association Between Hormonal Contraceptives and Lower Extremity Injuries in Female Athletes With Sports-Related Clinical Encountershttps://www.pharmaradar360.com/article/uncertainty-and-novel-clinical-trial-designs-in-oncology-when-should-equipoise-m-9d09e54cf8511c76PharmaRadar360en2026-09-11T00:00:00.000ZUncertainty and novel clinical trial designs in oncology – when should equipoise matter?https://www.pharmaradar360.com/article/mitral-regurgitation-and-severe-aortic-stenosis-clinical-characteristics-prognos-56a6b86519668248PharmaRadar360en2026-09-11T00:00:00.000ZMitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From Egnite Datahttps://www.pharmaradar360.com/article/spatiotemporal-mapping-of-tertiary-lymphoid-structure-heterogeneity-shapes-immun-b878c7a6750a845ePharmaRadar360en2026-09-11T00:00:00.000ZSpatiotemporal mapping of tertiary lymphoid structure heterogeneity shapes immune niches and clinical outcomes in intrahepatic cholangiocarcinomahttps://www.pharmaradar360.com/article/lignan-rich-norway-spruce-i-picea-abies-i-resin-extract-exhibits-anti-inflammato-bbbefd8591a7808aPharmaRadar360en2026-09-11T00:00:00.000ZLignan‐rich Norway spruce ( <i>Picea abies</i> ) resin extract exhibits anti‐inflammatory, skin‐regenerative and anti‐acne effects: In vitro, in silico, biocompatibility and exploratory clinical findingshttps://www.pharmaradar360.com/article/alcohol-and-other-drug-policies-for-health-care-workplaces-evaluation-of-the-con-e99cec33373f8f7bPharmaRadar360en2026-09-11T00:00:00.000ZAlcohol and other drug policies for health care workplaces: evaluation of the content, quality and implementabilityhttps://www.pharmaradar360.com/article/integrating-public-health-advertising-and-the-health-belief-model-to-predict-dia-a0939aee5e67c757PharmaRadar360en2026-09-11T00:00:00.000ZIntegrating public health advertising and the health belief model to predict diabetes prevention intention: evidence from Indonesian young generationshttps://www.pharmaradar360.com/article/interesting-hurdles-in-the-solution-of-pharmaceutical-crystal-structures-using-p-3e514e35adab43a8PharmaRadar360en2026-09-11T00:00:00.000ZInteresting hurdles in the solution of pharmaceutical crystal structures using powder diffraction datahttps://www.pharmaradar360.com/article/what-factors-are-associated-with-shoulder-joint-pain-in-male-swimmers-including-2d4ac870140b4056PharmaRadar360en2026-09-11T00:00:00.000ZWhat Factors Are Associated With Shoulder Joint Pain in Male Swimmers? Including Thoracic Kyphosis Anglehttps://www.pharmaradar360.com/article/optimized-dosing-of-momelotinib-in-myelofibrosis-through-quantitative-medicine-a-82759c408af8a2d1PharmaRadar360en2026-09-11T00:00:00.000ZOptimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentaryhttps://www.pharmaradar360.com/article/implementing-structured-and-collaborative-clinical-planning-for-comprehensive-hi-2ee6f77428200007PharmaRadar360en2026-09-11T00:00:00.000ZImplementing structured and collaborative clinical planning for Comprehensive, High-Dose Aphasia Treatment (CHAT): a pilot implementation-feasibility studyhttps://www.pharmaradar360.com/article/from-daffodils-to-drug-leads-amaryllidaceae-alkaloids-target-protein-translation-d152f81dc448462fPharmaRadar360en2026-09-11T00:00:00.000ZFrom Daffodils to Drug Leads: Amaryllidaceae Alkaloids Target Protein Translation in Chronic Lymphocytic Leukemia to Induce Selective Apoptosishttps://www.pharmaradar360.com/article/maladaptive-movement-in-eating-disorders-clinical-correlates-and-cross-cultural-88f05d3f85a94292PharmaRadar360en2026-09-11T00:00:00.000ZMaladaptive movement in eating disorders: clinical correlates and cross-cultural adaptation of the Czech exercise and eating disorders questionnairehttps://www.pharmaradar360.com/article/gut-microecology-and-cardiovascular-disease-core-pathogenic-mechanisms-and-clini-3c2babc6119fff71PharmaRadar360en2026-09-11T00:00:00.000ZGut microecology and cardiovascular disease: core pathogenic mechanisms and clinical intervention strategieshttps://www.pharmaradar360.com/article/oligoclonal-band-count-as-a-marker-of-mri-lesion-burden-and-clinical-profile-in-750eee9cb00a292ePharmaRadar360en2026-09-11T00:00:00.000ZOligoclonal band count as a marker of MRI lesion burden and clinical profile in newly diagnosed multiple sclerosishttps://www.pharmaradar360.com/article/clinical-and-mri-features-associated-with-remission-following-biological-therapy-0d857f7086779929PharmaRadar360en2026-09-11T00:00:00.000ZClinical and MRI features associated with remission following biological therapy in axial spondyloarthritishttps://www.pharmaradar360.com/article/repeated-perioperative-hypersensitivity-reactions-and-positive-challenge-testing-a6d40ff19fd054a0PharmaRadar360en2026-09-11T00:00:00.000ZRepeated perioperative hypersensitivity reactions and positive challenge testing strongly suggest sevoflurane hypersensitivity: a clinical report with supportive basophil activation testinghttps://www.pharmaradar360.com/article/safety-of-nonsteroidal-anti-inflammatory-drug-use-in-traumatic-brain-injury-579799c9f9af014aPharmaRadar360en2026-09-11T00:00:00.000ZSafety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/pharmacokinetics-of-loading-dose-vigabatrin-administered-via-enteral-tube-in-par-90af192c98b082d8PharmaRadar360en2026-09-11T00:00:00.000ZPharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticushttps://www.pharmaradar360.com/article/biotech-s-2026-ipos-deliver-broad-gains-through-august-5be01e38f285a85aPharmaRadar360en2026-09-10T23:40:00.000ZBiotech’s 2026 IPOs deliver broad gains through Augusthttps://www.pharmaradar360.com/article/ctt-pharmaceutical-holdings-ceo-ryan-khouri-buys-175-in-stock-ba8ba3e61a362f04PharmaRadar360en2026-09-10T23:31:00.000ZCTT Pharmaceutical Holdings CEO Ryan Khouri buys $175 in stockhttps://www.pharmaradar360.com/article/clinical-trials-new-mrna-cancer-vaccine-plus-keytruda-sharply-improves-melanoma-77a6de9d73d0071dPharmaRadar360en2026-09-10T22:14:55.000ZClinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survivalhttps://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92aPharmaRadar360en2026-09-10T22:07:51.000ZFDA withdraws publication of COVID, shingles vaccine research findingshttps://www.pharmaradar360.com/article/presidential-leadership-series-features-trustee-and-former-takeda-ceo-christophe-38714faec7ed3737PharmaRadar360en2026-09-10T21:57:24.000ZPresidential Leadership Series features trustee and former Takeda CEO Christophe Weberhttps://www.pharmaradar360.com/article/cpc-biotech-multiply-labs-develop-robot-ready-cell-therapy-connector-21a5a057220ff310PharmaRadar360en2026-09-10T21:54:01.000ZCPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connectorhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-sr-vp-chief-hr-officer-sold-shares-worth-over-2-7m-e4a012d0bc83cc78PharmaRadar360en2026-09-10T21:40:01.000ZWest Pharmaceutical Services Sr. VP & Chief HR Officer Sold Shares Worth Over $2.7Mhttps://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-hr-chief-sells-stock-outside-a-10b5-1-plan-f09f4eb3b8e82826PharmaRadar360en2026-09-10T21:37:29.000ZWest Pharmaceutical (NYSE: WST) HR chief sells stock outside a 10b5-1 planhttps://www.pharmaradar360.com/article/european-regulators-prepare-the-pharma-industry-for-future-changes-as-legislatio-fea13585a4f31be1PharmaRadar360en2026-09-10T21:32:04.000ZEuropean Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalizedhttps://www.pharmaradar360.com/article/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-the-b453b9741c0dd011PharmaRadar360en2026-09-10T21:10:38.000ZNew Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorderhttps://www.pharmaradar360.com/article/david-samra-calls-for-novartis-board-shake-up-pharmexec-d325baf3d1a4dd3ePharmaRadar360en2026-09-10T21:06:46.000ZDavid Samra Calls For Novartis Board Shake-Up | PharmExechttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-8d201788bc6ff87cPharmaRadar360en2026-09-10T21:04:00.000ZWest Pharmaceutical Services Inc. stock outperforms competitors on strong trading dayhttps://www.pharmaradar360.com/article/krystal-biotech-at-cantor-healthcare-conference-pipeline-gains-pace-da48474dd512d462PharmaRadar360en2026-09-10T20:42:26.000ZKrystal Biotech at Cantor healthcare conference: pipeline gains pacehttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-10T20:26:20.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/west-pharmaceutical-nyse-wst-awards-ceo-37k-options-and-14-8k-rsus-vesting-throu-02890534117bc52aPharmaRadar360en2026-09-10T19:40:52.000ZWest Pharmaceutical (NYSE: WST) awards CEO 37K options and 14.8K RSUs vesting through 2031https://www.pharmaradar360.com/article/precision-trading-with-fortress-biotech-inc-9-375-series-a-cumulative-redeemable-7b2183f89cc3ac84PharmaRadar360en2026-09-10T19:10:02.000ZPrecision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zoneshttps://www.pharmaradar360.com/article/committee-will-weigh-biotech-innovation-against-security-risks-6d75b2b5f7c94bf9PharmaRadar360en2026-09-10T18:42:02.000ZCommittee Will Weigh Biotech Innovation Against Security Riskshttps://www.pharmaradar360.com/article/biohaven-shares-plunge-as-fda-halts-new-enrollment-in-epilepsy-drug-trials-ba8d221d153c02a0PharmaRadar360en2026-09-10T18:41:00.000ZBiohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trialshttps://www.pharmaradar360.com/article/encoded-secures-275m-for-dravet-syndrome-gene-therapy-ac2b33bda3009e77PharmaRadar360en2026-09-10T18:37:59.000ZEncoded secures $275m for Dravet syndrome gene therapyhttps://www.pharmaradar360.com/article/fda-seeks-public-input-on-advancing-botanical-drug-development-ed74359bca572fc5PharmaRadar360en2026-09-10T18:25:00.000ZFDA seeks public input on advancing botanical drug developmenthttps://www.pharmaradar360.com/article/abbvie-declares-quarterly-dividend-260df77eb2bfb636PharmaRadar360en2026-09-10T18:25:00.000ZAbbVie Declares Quarterly Dividendhttps://www.pharmaradar360.com/article/5-best-psychedelic-stocks-for-2026-and-how-to-invest-723c0a3c104e3b21PharmaRadar360en2026-09-10T18:18:00.000Z5 Best Psychedelic Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/chemical-structure-formula-and-name-support-written-description-of-pharmaceutica-1d77f969ae2d3e5cPharmaRadar360en2026-09-10T18:11:11.000ZChemical Structure, Formula, and Name Support Written Description of Pharmaceutical Genushttps://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-advances-toward-phase-2-multiple-sclerosis-trial-af-2e6eaca0773422e8PharmaRadar360en2026-09-10T17:53:05.000ZQuantum BioPharma's Lucid-MS Advances Toward Phase 2 Multiple Sclerosis Trial After FDA Clearancehttps://www.pharmaradar360.com/article/hplc-degasser-upgraded-biotech-fluidics-launches-the-degasi-ng-platform-28b7579689b125bfPharmaRadar360en2026-09-10T17:03:35.000ZHPLC Degasser Upgraded: Biotech Fluidics Launches the DEGASi NG Platformhttps://www.pharmaradar360.com/article/pharmaceutical-products-with-device-only-patents-a-cross-sectional-analysis-5b12204246d6eec3PharmaRadar360en2026-09-10T16:47:20.000ZPharmaceutical products with device-only patents: a cross-sectional analysishttps://www.pharmaradar360.com/article/anmat-actualiza-los-criterios-regulatorios-para-software-como-dispositivo-medico-ce78e29882f4f325PharmaRadar360en2026-09-10T16:46:49.000ZANMAT actualiza los criterios regulatorios para software como dispositivo médico (SaMD)https://www.pharmaradar360.com/article/abbvie-drug-shows-significant-reductions-in-menstrual-migraine-days-0a66926b0c3b14b1PharmaRadar360en2026-09-10T16:41:18.000ZAbbVie Drug Shows Significant Reductions in Menstrual Migraine Dayshttps://www.pharmaradar360.com/article/biotech-news-from-around-the-world-96b51f3fd7c4a507PharmaRadar360en2026-09-10T16:40:00.000ZBiotech news from around the worldhttps://www.pharmaradar360.com/article/seattle-biotech-brainchild-bio-raises-116m-to-advance-car-t-therapy-for-childhoo-6c114812ad208cfbPharmaRadar360en2026-09-10T16:34:59.000ZSeattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancerhttps://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2025-to-march-2026-02e29b54f45a8fc7PharmaRadar360en2026-09-10T16:26:03.000ZNHS injury costs recovery scheme: April 2025 to March 2026https://www.pharmaradar360.com/article/best-biotech-stocks-to-add-to-your-watchlist-september-10th-d8ab2eff220ca406PharmaRadar360en2026-09-10T16:04:13.000ZBest Biotech Stocks To Add to Your Watchlist - September 10thhttps://www.pharmaradar360.com/article/xocova-offers-new-post-exposure-covid-19-prevention-option-for-adolescents-180741a4ba145920PharmaRadar360en2026-09-10T15:57:58.000ZXOCOVA offers new post-exposure COVID-19 prevention option for adolescentshttps://www.pharmaradar360.com/article/hsil-extends-biotech-index-to-malaysia-s-warrant-market-7d7be353577cf20ePharmaRadar360en2026-09-10T15:26:05.000ZHSIL extends biotech index to Malaysia’s warrant markethttps://www.pharmaradar360.com/article/kala-shankle-on-what-comes-next-for-national-licensure-74efa622bca91473PharmaRadar360en2026-09-10T15:23:58.000ZKala Shankle on What Comes Next for National Licensurehttps://www.pharmaradar360.com/article/minister-agrees-to-review-pharmacy-amendments-to-health-bill-46a2c884d11eb4a4PharmaRadar360en2026-09-10T15:19:58.000ZMinister agrees to review pharmacy amendments to Health Billhttps://www.pharmaradar360.com/article/ai-changes-the-how-not-the-what-ccddb8218dba7492PharmaRadar360en2026-09-10T15:15:19.000ZAI Changes The How, Not The Whathttps://www.pharmaradar360.com/article/roivant-at-citi-summit-cash-rich-biotech-leans-on-three-pillars-60ac4a42be1a796fPharmaRadar360en2026-09-10T14:55:43.000ZRoivant at Citi summit: cash-rich biotech leans on three pillarshttps://www.pharmaradar360.com/article/phase-3-trial-of-experimental-dm1-treatment-fails-to-hit-main-goal-47fea7492ee4aa03PharmaRadar360en2026-09-10T14:54:00.000ZPhase 3 trial of experimental DM1 treatment fails to hit main goalhttps://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-2130c9870ed50f98PharmaRadar360en2026-09-10T14:45:12.000ZUS FDA pauses new enrollment in Biohaven's epilepsy drug trialshttps://www.pharmaradar360.com/article/burning-rock-biotech-limited-reports-earnings-results-for-the-second-quarter-end-fe9932e3452b9015PharmaRadar360en2026-09-10T14:37:54.000ZBurning Rock Biotech Limited Reports Earnings Results for the Second Quarter Ended June 30, 2026https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-dfd4d9a9539fb316PharmaRadar360en2026-09-10T14:36:34.000ZUS FDA pauses new enrollment in Biohaven’s epilepsy drug trialshttps://www.pharmaradar360.com/article/fifth-circuit-judges-press-louisiana-on-standing-as-mifepristone-stays-available-7803e41623ffd424PharmaRadar360en2026-09-10T14:30:35.000ZFifth Circuit Judges Press Louisiana on Standing as Mifepristone Stays Available by Mail with No Ruling Yethttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharmaRadar360en2026-09-10T14:30:03.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831PharmaRadar360en2026-09-10T14:30:03.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharmaRadar360en2026-09-10T14:30:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharmaRadar360en2026-09-10T14:30:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1PharmaRadar360en2026-09-10T14:30:03.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75PharmaRadar360en2026-09-10T14:30:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharmaRadar360en2026-09-10T14:30:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharmaRadar360en2026-09-10T14:30:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86PharmaRadar360en2026-09-10T14:30:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/how-past-endpoints-11-winners-fared-as-the-biotech-industry-rebounded-b43f9ce8182c04f8PharmaRadar360en2026-09-10T14:30:00.000ZHow past Endpoints 11 winners fared as the biotech industry reboundedhttps://www.pharmaradar360.com/article/pharmaceutical-security-market-competitive-landscape-analyzed-across-leading-glo-ae872b3a3ec772bdPharmaRadar360en2026-09-10T14:30:00.000ZPharmaceutical Security Market Competitive Landscape Analyzed Across Leading Global Companieshttps://www.pharmaradar360.com/article/greater-philadelphia-regional-life-sciences-roundup-september-10-2026-a692fddd69a19c9dPharmaRadar360en2026-09-10T14:28:42.000ZGreater Philadelphia – Regional Life Sciences Roundup – September 10, 2026https://www.pharmaradar360.com/article/glenmark-and-south-piedmont-open-2-7-million-pharmaceutical-training-facility-0b4260fbc2643d82PharmaRadar360en2026-09-10T14:18:32.000ZGlenmark and South Piedmont Open $2.7 Million Pharmaceutical Training Facilityhttps://www.pharmaradar360.com/article/fda-cracks-down-on-unsafe-food-banned-products-17cbcad470576ff1PharmaRadar360en2026-09-10T14:14:27.000ZFDA cracks down on unsafe food, banned productshttps://www.pharmaradar360.com/article/stalled-generous-globe-and-guard-initiatives-create-international-pricing-uncert-01e4dff956d74dffPharmaRadar360en2026-09-10T14:13:42.000ZStalled GENEROUS, GLOBE, and GUARD Initiatives Create International Pricing Uncertainty for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/what-health-equity-champions-can-learn-from-pharmaceutical-sales-9d780c13222a1501PharmaRadar360en2026-09-10T13:59:06.000ZWhat Health Equity Champions Can Learn from Pharmaceutical Saleshttps://www.pharmaradar360.com/article/fda-places-partial-hold-on-biohaven-s-ion-channel-drug-f305595bf9c3c703PharmaRadar360en2026-09-10T13:58:00.000ZFDA places partial hold on Biohaven’s ion channel drughttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharmaRadar360en2026-09-10T13:52:44.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/maharashtra-fda-raids-11-food-units-in-thane-seizes-materials-worth-rs-20-48-lak-9f75fd7cc7276ce7PharmaRadar360en2026-09-10T13:47:26.000ZMaharashtra FDA Raids 11 Food Units in Thane, Seizes Materials Worth Rs 20.48 Lakhhttps://www.pharmaradar360.com/article/frazier-life-sciences-nets-1-1b-in-long-running-fund-aimed-at-small-midsize-biot-6cbd4c5bcf9742ebPharmaRadar360en2026-09-10T13:44:14.000ZFrazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechshttps://www.pharmaradar360.com/article/adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbvie-pending-5dba419255f531e9PharmaRadar360en2026-09-10T13:41:31.000ZADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX)https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-agreement-with-national-cance-9c28ffcdb1c0cf0fPharmaRadar360en2026-09-10T13:40:47.000ZIMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001https://www.pharmaradar360.com/article/fda-expands-bayer-lung-cancer-drug-approval-71178ea7131e5c0aPharmaRadar360en2026-09-10T13:39:34.000ZFDA expands Bayer lung cancer drug approvalhttps://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-b0c70810964568e8PharmaRadar360en2026-09-10T13:33:05.000ZScenic Biotech appoints renowned neurology drug development leader Dr. Judith Walker as Chief Medical Officerhttps://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60PharmaRadar360en2026-09-10T13:33:00.000ZCullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/samsung-biologics-signs-usd-262-million-manufacturing-agreement-with-european-ph-d2defa9f379bb988PharmaRadar360en2026-09-10T13:32:47.000ZSamsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical companyhttps://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-4ff7c827c11dfc18PharmaRadar360en2026-09-10T13:30:00.000ZIMUNON Enters Cooperative Research and Developmenthttps://www.pharmaradar360.com/article/west-pharmaceutical-services-at-wells-fargo-conference-growth-outlook-lifts-7e95f35a8d9d2806PharmaRadar360en2026-09-10T13:29:00.000ZWest Pharmaceutical Services at Wells Fargo conference: growth outlook liftshttps://www.pharmaradar360.com/article/scynexis-appoints-sanjay-subramanian-cfo-as-biotech-advances-rare-disease-pipeli-7ffff17544555b0fPharmaRadar360en2026-09-10T13:28:31.000ZSCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipelinehttps://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abbPharmaRadar360en2026-09-10T13:27:33.000ZMajor expansion of community mental health support across Englandhttps://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-5a32cb9618b921d8PharmaRadar360en2026-09-10T13:26:47.000ZmRNA cancer vaccines’ biggest barriers to markethttps://www.pharmaradar360.com/article/takeda-s-long-serving-r-d-chief-andy-plump-to-retire-in-wake-of-pipeline-success-59af07bbf36e86fbPharmaRadar360en2026-09-10T13:25:30.000ZTakeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successeshttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964PharmaRadar360en2026-09-10T13:25:15.000ZFrazier Life Sciences adds $1.1B to biotech public fund, lifting it to $2.8Bhttps://www.pharmaradar360.com/article/burning-rock-biotech-releases-q2-2026-financial-results-8819331f3d074a9aPharmaRadar360en2026-09-10T13:22:28.000ZBurning Rock Biotech Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/update-starton-therapeutics-to-present-at-medinvest-biotech-pharma-conference-d467c5ff3d6873ebPharmaRadar360en2026-09-10T13:19:11.000ZUPDATE -- Starton Therapeutics to Present at MedInvest Biotech & Pharma Conferencehttps://www.pharmaradar360.com/article/biotech-pre-market-movers-tnon-aeon-surge-coo-cdt-slide-a99c6eadfee151c8PharmaRadar360en2026-09-10T13:17:00.000ZBiotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slidehttps://www.pharmaradar360.com/article/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-4c45ecc8dc428588PharmaRadar360en2026-09-10T13:16:03.000ZBiovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidatehttps://www.pharmaradar360.com/article/25f1670-gloflon-i-v-catheter-with-injection-valves-wings-20g-1-1-x-33mm-666903112fb8586ePharmaRadar360en2026-09-10T13:12:22.000ZΑνάκληση της παρτίδας 25F1670 του Ιατροτεχνολογικού προϊόντος Gloflon I.V. CATHETER WITH INJECTION VALVES & WINGS 20G 1.1 x 33mmhttps://www.pharmaradar360.com/article/cannara-biotech-secures-58m-credit-facility-with-bmo-and-td-5c15a8e996887473PharmaRadar360en2026-09-10T13:07:15.000ZCannara Biotech secures $58M credit facility with BMO and TDhttps://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44PharmaRadar360en2026-09-10T13:06:45.000ZLatest figures highlight ongoing Meningitis B risk for studentshttps://www.pharmaradar360.com/article/burning-rock-q2-revenue-falls-9-3-to-rmb134-7m-cafe7127e11ce51ePharmaRadar360en2026-09-10T13:04:51.000ZBurning Rock Q2 revenue falls 9.3% to RMB134.7Mhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090PharmaRadar360en2026-09-10T13:00:00.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69PharmaRadar360en2026-09-10T13:00:00.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-6a69b46a841b8f13PharmaRadar360en2026-09-10T12:55:00.000ZNo treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial.https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-aa42924a07011e55PharmaRadar360en2026-09-10T12:55:00.000ZAbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migrainehttps://www.pharmaradar360.com/article/pharma-pulse-dhl-s-new-singapore-hub-and-pharma-rethinks-go-to-market-6f1e39d1bd379b78PharmaRadar360en2026-09-10T12:53:51.000ZPharma Pulse: DHL's New Singapore Hub and Pharma Rethinks Go-To Markethttps://www.pharmaradar360.com/article/geovax-provides-nasdaq-listing-update-and-reaffirms-focus-on-advancing-strategic-e2e455613a5a2210PharmaRadar360en2026-09-10T12:37:21.000ZGeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Prioritieshttps://www.pharmaradar360.com/article/unlocking-cell-surface-protein-research-with-site-specific-labelling-4b2c27c5d4f0630dPharmaRadar360en2026-09-10T12:34:43.000ZUnlocking Cell Surface Protein Research with Site-Specific Labellinghttps://www.pharmaradar360.com/article/oncolytics-biotech-reports-preclinical-pelareorep-activity-maintained-with-ras-i-acb108f11ddc1118PharmaRadar360en2026-09-10T12:21:00.000ZOncolytics Biotech Reports Preclinical Pelareorep Activity Maintained with RAS Inhibitionhttps://www.pharmaradar360.com/article/daesang-expands-into-pharmaceutical-grade-amino-acids-7525345f8975eea5PharmaRadar360en2026-09-10T12:15:44.000ZDaesang expands into pharmaceutical-grade amino acidshttps://www.pharmaradar360.com/article/an-experimental-cancer-treatment-combination-reduced-tumor-growth-in-early-tests-915d2ac78c60b6c6PharmaRadar360en2026-09-10T12:15:00.000ZAn experimental cancer treatment combination reduced tumor growth in early testshttps://www.pharmaradar360.com/article/an-investigational-cell-therapy-for-alzheimer-s-and-parkinson-s-will-be-presente-9bd92b46dfeadd3fPharmaRadar360en2026-09-10T12:05:00.000ZAn investigational cell therapy for Alzheimer’s and Parkinson’s will be presented in Korea.https://www.pharmaradar360.com/article/a-look-at-cleanassure-by-freudenberg-medical-1781dee31e7a4af8PharmaRadar360en2026-09-10T12:00:38.000ZA look at CleanAssure by Freudenberg Medicalhttps://www.pharmaradar360.com/article/imn-screws-system-advanced-locking-screw-ec5f499d9db6b051PharmaRadar360en2026-09-10T12:00:00.000ZIMN Screws System Advanced Locking Screwhttps://www.pharmaradar360.com/article/generic-acetaminophen-by-teva-recalled-because-it-may-contain-foreign-material-7343823d673bcc9fPharmaRadar360en2026-09-10T12:00:00.000ZGeneric acetaminophen by Teva recalled because it may contain foreign materialhttps://www.pharmaradar360.com/article/dxc-500i-clinical-analyzer-and-dxc-500-au-clinical-chemistry-analyzer-0e5e9773dfcba50dPharmaRadar360en2026-09-10T12:00:00.000ZDxc 500i Clinical Analyzer and Dxc 500 AU Clinical Chemistry Analyzerhttps://www.pharmaradar360.com/article/centricity-high-acuity-anesthesia-2ada63128acd97ccPharmaRadar360en2026-09-10T12:00:00.000ZCentricity High Acuity Anesthesiahttps://www.pharmaradar360.com/article/data-on-five-year-remission-with-a-myeloma-treatment-will-be-presented-in-scotla-a31339569a772091PharmaRadar360en2026-09-10T12:00:00.000ZData on five-year remission with a myeloma treatment will be presented in Scotlandhttps://www.pharmaradar360.com/article/why-is-biohaven-pharmaceutical-stock-sliding-today-d8352213f625eea5PharmaRadar360en2026-09-10T11:46:41.000ZWhy is Biohaven Pharmaceutical stock sliding today?https://www.pharmaradar360.com/article/a-booming-business-on-wall-street-would-love-more-biotechs-to-quietly-die-23a99c530fc41a86PharmaRadar360en2026-09-10T11:46:27.000ZA booming business on Wall Street would love more biotechs to quietly diehttps://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8fPharmaRadar360en2026-09-10T11:35:38.000ZData Aggregation Drives AI's Impact on Clinical Supply Chainshttps://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-8e9e18b565ad084ePharmaRadar360en2026-09-10T11:34:16.000ZCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026https://www.pharmaradar360.com/article/3145507-hippokratis-10x20-ply-ref-1020121301-070cc64470b4812dPharmaRadar360en2026-09-10T11:33:51.000ZΑνάκληση της παρτίδας 3145507 του ιατροτεχνολογικού προϊόντος HIPPOKRATIS Επιθέματα γάζας μη αποστειρωμένα 10X20 PLY, REF: 1020121301https://www.pharmaradar360.com/article/biotech-hair-brand-vegamour-snapped-up-by-kvd-beauty-owner-belle-brands-9e5b5f7223daebe3PharmaRadar360en2026-09-10T11:30:39.000ZBiotech hair brand Vegamour snapped up by KVD Beauty owner Belle Brandshttps://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-93171a452257b7a9PharmaRadar360en2026-09-10T11:30:00.000ZCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026https://www.pharmaradar360.com/article/burning-rock-biotech-s-q2-revenue-falls-net-loss-widens-on-central-laboratory-we-3a2bfe5a57b7c6c6PharmaRadar360en2026-09-10T11:29:04.000ZBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weaknesshttps://www.pharmaradar360.com/article/burning-rock-biotech-reports-second-quarter-2026-financial-results-and-business-3604b6a838f831f6PharmaRadar360en2026-09-10T11:20:00.000ZBurning Rock Biotech Reports Second Quarter 2026 Financial Results and Business Updateshttps://www.pharmaradar360.com/article/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-appl-173e26866817c76ePharmaRadar360en2026-09-10T11:13:17.000ZPrelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degraderhttps://www.pharmaradar360.com/article/can-simulation-help-foundation-trainee-pharmacists-prepare-for-prescribing-754b389753a9f647PharmaRadar360en2026-09-10T11:12:33.000ZCan simulation help foundation trainee pharmacists prepare for prescribing?https://www.pharmaradar360.com/article/migraine-and-acne-included-in-new-prescribing-pharmacy-first-pathways-3ea2469614a56a9cPharmaRadar360en2026-09-10T11:12:33.000ZMigraine and acne included in new prescribing Pharmacy First pathwayshttps://www.pharmaradar360.com/article/uzbekistan-pharmaceutical-output-reaches-uzs-3-5-trillion-in-seven-months-e698870d82152c1bPharmaRadar360en2026-09-10T11:10:20.000ZUzbekistan Pharmaceutical Output Reaches UZS 3.5 Trillion in Seven Monthshttps://www.pharmaradar360.com/article/phase-1-2-clinical-trial-of-opgx-best1-shows-positive-results-for-inherited-reti-693efb757e3769e0PharmaRadar360en2026-09-10T11:09:11.000ZPhase 1/2 clinical trial of OPGx-BEST1 shows positive results for inherited retinal diseaseshttps://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75PharmaRadar360en2026-09-10T11:00:34.000ZPodcast: key readouts from ESC and ERShttps://www.pharmaradar360.com/article/new-suicide-risk-research-will-join-five-posters-on-a-treatment-e30968146e5d4bbaPharmaRadar360en2026-09-10T11:00:00.000ZNew suicide-risk research will join five posters on a treatmenthttps://www.pharmaradar360.com/article/sk-biopharm-s-in-licensed-epilepsy-drug-opcalim-hits-partial-fda-clinical-hold-58e7c243c85a1a2cPharmaRadar360en2026-09-10T10:55:00.000ZSK Biopharm's In-Licensed Epilepsy Drug OPCALIM Hits Partial FDA Clinical Holdhttps://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3PharmaRadar360en2026-09-10T10:52:30.000ZHHS appoints permanent FDA CBER, CDER headshttps://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9PharmaRadar360en2026-09-10T10:48:05.000ZSpain pushes for ‘access toolbox’ in EU biotech ruleshttps://www.pharmaradar360.com/article/inauguration-ceremony-of-the-nafdac-pharmacist-reserve-group-3142b109dbb0e447PharmaRadar360en2026-09-10T10:45:10.000ZInauguration Ceremony of the NAFDAC Pharmacist Reserve Grouphttps://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-078244ed36863e9cPharmaRadar360en2026-09-10T10:40:59.000ZUS appeals court skeptical of bid to curtail abortion pill accesshttps://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3PharmaRadar360en2026-09-10T10:39:00.000ZJoin the Danish Medicines Agency’s ATMP Open Househttps://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734PharmaRadar360en2026-09-10T10:36:24.000ZWhat to expect from UniQure’s upcoming Huntington’s gene therapy readouthttps://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3PharmaRadar360en2026-09-10T10:36:24.000ZRoivant is one of the savviest dealmakers in biotech. It also has a secret weaponhttps://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03PharmaRadar360en2026-09-10T10:16:39.000ZSquarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RAREhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9dfPharmaRadar360en2026-09-10T10:11:00.000ZTeva Pharmaceutical Industries Prices $4.9 Billion Senior Notes Offering and Announces Conditional Redemptionshttps://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13PharmaRadar360en2026-09-10T10:00:00.000ZPower Optimization Solution Ends Costly Grid-Related Shutdowns at Major Pharmaceutical Manufacturing Planthttps://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32PharmaRadar360en2026-09-10T09:46:00.000ZActive Pharmaceutical Ingredients Market Demand Insightshttps://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1aPharmaRadar360en2026-09-10T09:44:09.000ZOne assessment, 27 countries: how EU joint reviews workhttps://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809PharmaRadar360en2026-09-10T09:36:31.000ZWhen the ER Is Not an Option: Milestone’s CMO on Bringing AFib Rate Control Homehttps://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ffPharmaRadar360en2026-09-10T09:34:28.000ZTakeda Pharmaceutical Co Ltd - Takeda Announces Planned Retirement Of President Of Research & Development Andy Plump Effective June 2027https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888PharmaRadar360en2026-09-10T09:34:06.000ZTakeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plumphttps://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813PharmaRadar360en2026-09-10T09:33:40.000ZSystech launches TraceIQhttps://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bfd0e22feb57c6cbPharmaRadar360en2026-09-10T09:31:00.000ZHow UD's STAR Campus is helping companies foster innovation in biotechhttps://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77bPharmaRadar360en2026-09-10T09:24:00.000ZBiotech Growth Trust Stands Out In A Stronger Biotechnology Sectorhttps://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0PharmaRadar360en2026-09-10T09:19:00.000ZME Therapeutics Stock Faces Downside Pressure as Biotech Risk and Preclinical Uncertainty Weigh on Sentimenthttps://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259aPharmaRadar360en2026-09-10T09:16:00.000ZBioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Boardhttps://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2PharmaRadar360en2026-09-10T09:10:10.000ZYourgene Insight DPYD assay gets IVDR accreditationhttps://www.pharmaradar360.com/article/fda-places-partial-clinical-hold-on-sk-biopharm-s-epilepsy-drug-candidate-opacal-826dea09fcfc58ccPharmaRadar360en2026-09-10T09:10:05.000ZFDA places partial clinical hold on SK Biopharm's epilepsy drug candidate opacalimhttps://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715cePharmaRadar360en2026-09-10T09:00:00.000Zエンスプリングに関するロシュ社の発表について（MOG抗体関連疾患に対するFDAによる申請受理および優先審査指定）https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2PharmaRadar360en2026-09-10T09:00:00.000ZRoche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3adPharmaRadar360en2026-09-10T08:55:00.000ZSamsung Biologics Signs ₩350.8 Billion Long-Term CMO Deal with European Pharmaceutical Companyhttps://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244PharmaRadar360en2026-09-10T08:47:40.000ZBiotech Fluidics launch DEGASi NG platformhttps://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48PharmaRadar360en2026-09-10T08:46:07.000ZDong-A Socio Holdings to rename itself Dong-A Pharmaceutical after OTC mergerhttps://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75PharmaRadar360en2026-09-10T08:35:23.000ZBiotech Fluidics upgrades its Degasi inline degasser rangehttps://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170daPharmaRadar360en2026-09-10T08:33:17.000ZWhy evidence matters: Seema Meloni on making data meaningfulhttps://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323PharmaRadar360en2026-09-10T08:30:10.000ZSalmonella outbreak updatehttps://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884PharmaRadar360en2026-09-10T08:30:07.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-10T08:30:05.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60PharmaRadar360en2026-09-10T08:30:04.000ZMeningococcal disease: laboratory-confirmed cases in England 2025 to 2026